Charlotte R. Bell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Charlotte R. Bell has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Bonavita
Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
59 shared publications - Santiago Zelenay
Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK
59 shared publications - Agrin Moeini
Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
55 shared publications - Charles H. Earnshaw
Dermatology Centre, Northern Care Alliance NHS Foundation Trust , Salford
39 shared publications - Maria A. Koufaki
Cancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
39 shared publications - Alexander R. Baker
Visualisation, Irradiation and Analysis, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
38 shared publications
Latest Publications
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Supplementary Figure 8. Topical GC treatment induces comparable systemic leukocyte reduction in parental and GRKO tumor-bearing mice.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Supplementary Figure 8. Topical GC treatment induces comparable systemic leukocyte reduction in parental and GRKO tumor-bearing mice.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Supplementary Figure 7. GCs do not act on immune cells to trigger tumor control.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Supplementary Figure 7. GCs do not act on immune cells to trigger tumor control.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Supplementary Figure 2. Topical GC treatment of 20967 tumors reduce leukocyte counts systemically.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Supplementary Figure 2. Topical GC treatment of 20967 tumors reduce leukocyte counts systemically.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Supplementary Figure 10. The TGF-β activating function of GARP is required for GC-induced tumor control.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Supplementary Figure 10. The TGF-β activating function of GARP is required for GC-induced tumor control.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Cluster biomarkers used for cell classification (Fig. 3).
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Cluster biomarkers used for cell classification (Fig. 3).
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
GSEA results for control- or GC-treated 20967 melanomas for the CD8, neutrophil and monocyte clusters related to Fig. 3.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
GSEA results for control- or GC-treated 20967 melanomas for the CD8, neutrophil and monocyte clusters related to Fig. 3.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Overlapping DEGs following GC-treatment in vivo and in vitro, leading to development of GC-stimulated gene signature (related to Fig. 4).
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Overlapping DEGs following GC-treatment in vivo and in vitro, leading to development of GC-stimulated gene signature (related to Fig. 4).
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Human GC-stimulated gene signature, developed from murine sequencing data (related to Supplementary Table 1).
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Human GC-stimulated gene signature, developed from murine sequencing data (related to Supplementary Table 1).
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
GSEA results for GC-treated parental and GRKO tumors in vivo related to Fig. 4.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
GSEA results for GC-treated parental and GRKO tumors in vivo related to Fig. 4.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Supplementary Figure 1. The 20967 melanoma model is resistant to immune checkpoint blockade.
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Glucocorticoids Unleash Immune-dependent Melanoma Control through Inhibition of the GARP/TGFβ Axis
Supplementary Figure 1. The 20967 melanoma model is resistant to immune checkpoint blockade.